Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03UZC
|
|||
| Former ID |
DIB001560
|
|||
| Drug Name |
DS-1150b
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Daiichi sankyo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose transporter type 4 (SLC2A4) | Target Info | Modulator | [2] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Insulin signaling pathway | ||||
| Adipocytokine signaling pathway | ||||
| Type II diabetes mellitus | ||||
| Pathwhiz Pathway | Glucose-Alanine Cycle | |||
| Insulin Signalling | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Insulin-mediated glucose transport | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | Translocation of GLUT4 to the plasma membrane | |||
| Transcriptional regulation of white adipocyte differentiation | ||||
| Facilitative Na+-independent glucose transporters | ||||
| Glucose transport | ||||
| WikiPathways | Glycolysis and Gluconeogenesis | |||
| Insulin Signaling | ||||
| NRF2 pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Translocation of GLUT4 to the Plasma Membrane | ||||
| Transcriptional Regulation of White Adipocyte Differentiation | ||||
| Adipogenesis | ||||
| Cori Cycle | ||||
| Hexose transport | ||||
| Type II diabetes mellitus | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02004678) Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus. U.S. National Institutesof Health. | |||
| REF 2 | Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.